First Time Loading...

AstraZeneca PLC
LSE:AZN

Watchlist Manager
AstraZeneca PLC Logo
AstraZeneca PLC
LSE:AZN
Watchlist
Price: 10 886 GBX -1.25% Market Closed
Updated: Apr 16, 2024

Intrinsic Value

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. [ Read More ]

The intrinsic value of one AZN stock under the Base Case scenario is 12 598.27 GBX. Compared to the current market price of 10 886 GBX, AstraZeneca PLC is Undervalued by 14%.

Key Points:
AZN Intrinsic Value
Base Case
12 598.27 GBX
Undervaluation 14%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
AstraZeneca PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AZN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
AstraZeneca PLC

Provide an overview of the primary business activities
of AstraZeneca PLC.

What unique competitive advantages
does AstraZeneca PLC hold over its rivals?

What risks and challenges
does AstraZeneca PLC face in the near future?

Summarize the latest earnings call
of AstraZeneca PLC.

What significant events have occurred
in AstraZeneca PLC over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for AstraZeneca PLC.

Provide P/S
for AstraZeneca PLC.

Provide P/E
for AstraZeneca PLC.

Provide P/OCF
for AstraZeneca PLC.

Provide P/FCFE
for AstraZeneca PLC.

Provide P/B
for AstraZeneca PLC.

Provide EV/S
for AstraZeneca PLC.

Provide EV/GP
for AstraZeneca PLC.

Provide EV/EBITDA
for AstraZeneca PLC.

Provide EV/EBIT
for AstraZeneca PLC.

Provide EV/OCF
for AstraZeneca PLC.

Provide EV/FCFF
for AstraZeneca PLC.

Provide EV/IC
for AstraZeneca PLC.

Show me price targets
for AstraZeneca PLC made by professional analysts.

What are the Revenue projections
for AstraZeneca PLC?

How accurate were the past Revenue estimates
for AstraZeneca PLC?

What are the Net Income projections
for AstraZeneca PLC?

How accurate were the past Net Income estimates
for AstraZeneca PLC?

What are the EPS projections
for AstraZeneca PLC?

How accurate were the past EPS estimates
for AstraZeneca PLC?

What are the EBIT projections
for AstraZeneca PLC?

How accurate were the past EBIT estimates
for AstraZeneca PLC?

Compare the revenue forecasts
for AstraZeneca PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of AstraZeneca PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of AstraZeneca PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of AstraZeneca PLC compared to its peers.

Compare the P/E ratios
of AstraZeneca PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing AstraZeneca PLC with its peers.

Analyze the financial leverage
of AstraZeneca PLC compared to its main competitors.

Show all profitability ratios
for AstraZeneca PLC.

Provide ROE
for AstraZeneca PLC.

Provide ROA
for AstraZeneca PLC.

Provide ROIC
for AstraZeneca PLC.

Provide ROCE
for AstraZeneca PLC.

Provide Gross Margin
for AstraZeneca PLC.

Provide Operating Margin
for AstraZeneca PLC.

Provide Net Margin
for AstraZeneca PLC.

Provide FCF Margin
for AstraZeneca PLC.

Show all solvency ratios
for AstraZeneca PLC.

Provide D/E Ratio
for AstraZeneca PLC.

Provide D/A Ratio
for AstraZeneca PLC.

Provide Interest Coverage Ratio
for AstraZeneca PLC.

Provide Altman Z-Score Ratio
for AstraZeneca PLC.

Provide Quick Ratio
for AstraZeneca PLC.

Provide Current Ratio
for AstraZeneca PLC.

Provide Cash Ratio
for AstraZeneca PLC.

What is the historical Revenue growth
over the last 5 years for AstraZeneca PLC?

What is the historical Net Income growth
over the last 5 years for AstraZeneca PLC?

What is the current Free Cash Flow
of AstraZeneca PLC?

AI Assistant can make mistakes. Consider checking important information.
Financials

Balance Sheet Decomposition
AstraZeneca PLC

Current Assets 25.1B
Cash & Short-Term Investments 6B
Receivables 13.6B
Other Current Assets 5.5B
Non-Current Assets 76.1B
Long-Term Investments 1.7B
PP&E 10.5B
Intangibles 58.1B
Other Non-Current Assets 5.7B
Current Liabilities 30.5B
Accounts Payable 22.4B
Short-Term Debt 515m
Other Current Liabilities 7.7B
Non-Current Liabilities 31.4B
Long-Term Debt 23.2B
Other Non-Current Liabilities 8.2B
Efficiency

Earnings Waterfall
AstraZeneca PLC

Revenue
45.8B USD
Cost of Revenue
-8.1B USD
Gross Profit
37.7B USD
Operating Expenses
-28.8B USD
Operating Income
8.9B USD
Other Expenses
-3B USD
Net Income
6B USD

Free Cash Flow Analysis
AstraZeneca PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AZN Profitability Score
Profitability Due Diligence

AstraZeneca PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Years Revenue Growth
Positive Operating Income
57/100
Profitability
Score

AstraZeneca PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

AZN Solvency Score
Solvency Due Diligence

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Average Altman Z-Score
Short-Term Solvency
46/100
Solvency
Score

AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AZN Price Targets Summary
AstraZeneca PLC

Wall Street analysts forecast AZN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AZN is 12 183.28 GBX with a low forecast of 5 999.55 GBX and a high forecast of 17 640 GBX.

Lowest
Price Target
5 999.55 GBX
45% Downside
Average
Price Target
12 183.28 GBX
12% Upside
Highest
Price Target
17 640 GBX
62% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

AZN Price
AstraZeneca PLC

1M 1M
+6%
6M 6M
+1%
1Y 1Y
-6%
3Y 3Y
+58%
5Y 5Y
+105%
10Y 10Y
+305%
Annual Price Range
10 886
52w Low
9 354.2809
52w High
12 026.4289
Price Metrics
Average Annual Return 21.24%
Standard Deviation of Annual Returns 16.97%
Max Drawdown -22%
Shares Statistics
Market Capitalization 168.8B GBX
Shares Outstanding 1 561 000 000
Percentage of Shares Shorted
N/A

AZN Return Decomposition
Main factors of price return

What is price return decomposition?

AZN News

Other Videos

Last Important Events
AstraZeneca PLC

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
AstraZeneca PLC

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

AstraZeneca PLC Logo
AstraZeneca PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

168.8B GBP

Dividend Yield

2.07%

Description

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The firm is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The firm has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Contact

CAMBRIDGESHIRE
Cambridge
1 Francis Crick Avenue
+11442073045000.0
https://www.astrazeneca.com/Home

IPO

2007-09-21

Employees

83 100

Officers

CEO & Executive Director
Mr. Pascal Soriot D.V.M., M.B.A.
CFO & Executive Director
Dr. Aradhana Sarin M.D.
EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Ms. Pam P. Cheng
Head of Investor Relations
Mr. Andrew P. Barnett
CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Mr. Jeffrey Pott
Head of Global Media Relations
Gonzalo Vina
Show More
Executive Vice-President
Dr. Menelas Nicolas Pangalos Ph.D.
Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Ruud Dobber Ph.D.
Executive Vice President of Oncology Research & Development
Dr. Susan Mary Galbraith M.D., Ph.D.
Executive VP of International & China President
Mr. Leon Wang
Show Less

See Also

Discover More
What is the Intrinsic Value of one AZN stock?

The intrinsic value of one AZN stock under the Base Case scenario is 12 598.27 GBX.

Is AZN stock undervalued or overvalued?

Compared to the current market price of 10 886 GBX, AstraZeneca PLC is Undervalued by 14%.